<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tubacin is a small molecule inhibitor of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase 6 and blocks aggresome activity </plain></SENT>
<SENT sid="1" pm="."><plain>We found that Epstein-Barr virus (EBV)-positive Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells were generally killed by lower doses of tubacin than EBV-transformed lymphoblastoid cells (LCLs) or EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>Tubacin induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of LCLs, which was inhibited by pretreatment with a pancaspase inhibitor but not by butylated hydroxyanisole, which inhibits reactive oxygen species </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, tubacin killed EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells in a caspase-3-independent pathway that involved reactive oxygen species and was blocked by butylated hydroxyanisole </plain></SENT>
<SENT sid="4" pm="."><plain>Previously, we showed that <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, a <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi>, induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of EBV LCLs and that LCLs are killed by lower doses of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> than EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>Here we found that the combination of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> and tubacin acted in synergy to kill EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells and LCLs </plain></SENT>
<SENT sid="6" pm="."><plain>Tubacin or the combination of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> and tubacin did not induce EBV lytic replication </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that the combination of a <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> and an HDAC6 inhibitor may represent a useful strategy for the treatment of certain EBV-associated B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>